{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:21:53Z","timestamp":1794532913621,"version":"4.9.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vector-Borne and Zoonotic Diseases"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is a need for updated incidence rates (IRs) of Lyme borreliosis (LB) in Europe, including the Netherlands. We estimated LB IRs stratified by geographic area, year, age, sex, immunocompromised status, and socioeconomic status (SES).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All subjects registered in the PHARMO General Practitioner (GP) Database without prior diagnosis of LB or disseminated LB and having \u22651 year of continuous database enrolment were included. IRs and corresponding confidence intervals (CIs) of GP-recorded LB, erythema migrans (EM), and disseminated LB were estimated during the period 2015\u20122019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 14,794 events (suspected, probable, or confirmed) with a diagnostic code for LB that included 8219 with a recorded clinical manifestation: 7985 (97%) with EM and 234 (3%) with disseminated LB. National annual LB IRs were relatively consistent, ranging from 111 (95% CI 106\u2012115) in 2019 to 131 (95% CI 126\u2012136) in 2018 per 100,000 person-years. Incidence of LB showed a bimodal age distribution, with peak IRs observed among subjects aged 5\u201214 and 60\u201269 years in men and women. Higher LB incidence was found in subjects who were residents of the provinces of Drenthe and Overijssel, immunocompromised, or of lower SES. Similar patterns were observed for EM and disseminated LB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings confirm that LB incidence remains substantial throughout the Netherlands with no indication of decline in the past 5 years. Foci in two provinces and among vulnerable populations suggest potential initial target groups for preventive strategies such as vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/vbz.2022.0048","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T11:44:14Z","timestamp":1681818254000},"page":"230-236","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence of Lyme Borreliosis in the Dutch General Practice Population: A Large-Scale Population-Based Cohort Study Across the Netherlands Between 2015 and 2019"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-3335","authenticated-orcid":false,"given":"Eline","family":"Houben","sequence":"first","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"de Jong","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernie","family":"Penning-van Beest","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephina","family":"Kuiper","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Holthuis","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Blum","sequence":"additional","affiliation":[{"name":"P95 Pharmacovigilance and Epidemiology, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozica","family":"Skufca","sequence":"additional","affiliation":[{"name":"P95 Pharmacovigilance and Epidemiology, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Riera-Montes","sequence":"additional","affiliation":[{"name":"P95 Pharmacovigilance and Epidemiology, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Vaccines Medical Development and Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pilz","sequence":"additional","affiliation":[{"name":"Pfizer Corporation, Vaccines Medical Development and Scientific and Clinical Affairs, Wien, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew John","family":"Vyse","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd., Walton Oaks, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Vaccines Medical Development and Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendwas","family":"Dzingina","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Patient Health &amp; Impact, Chief Business Office, Pfizer, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Herings","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands."},{"name":"Department of Epidemiology &amp; Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Stark","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Vaccines Medical Development and Scientific and Clinical Affairs, Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"crossref","unstructured":"Beard CB Eisen RJ Barker CM Garofalo JF et al. Chapter 5: Vector-borne diseases. In: The Impacts of Climate Change on Human Health in the United States: A Scientific Assessment. Washington DC: U.S. Global Change Research Program 2016. Available at http:\/\/dx.doi.org\/10.7930\/J0765C7V","DOI":"10.7930\/J0765C7V"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3146-2"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-018-0729-2"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.08.040"},{"key":"e_1_3_8_6_1","first-page":"665","article-title":"[Doubling of the number of cases of tick bites and lyme borreliosis seen by general practitioners in the Netherlands]","volume":"148","author":"den Boon S","year":"2004","unstructured":"den Boon S, , Schellekens JF, , Schouls LM, , Suijkerbuijk AW, et al. [Doubling of the number of cases of tick bites and lyme borreliosis seen by general practitioners in the Netherlands]. Ned Tijdschr Geneeskd, 2004; 148:665\u2013670.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33900-2"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2010.0026"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-021-04607-7"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3105-y"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-0777-6"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2014.09.006"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064361"},{"key":"e_1_3_8_14_1","article-title":"Lyme borreliosis in the Netherlands: Strong increase in GP consultations and hospital admissions in past 10 years","volume":"11","author":"Hofhuis A","year":"2006","unstructured":"Hofhuis A, , van der Giessen JW, , Borgsteede FH, , Wielinga PR, et al. Lyme borreliosis in the Netherlands: Strong increase in GP consultations and hospital admissions in past 10 years. Euro Surveill, 2006; 11:E060622.2.","journal-title":"Euro Surveill"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/322669"},{"key":"e_1_3_8_16_1","unstructured":"Kenniscentrum ree\u00ebn. Distribution of deer derived from spring census 2003. 2003. Available at https:\/\/www.over-reeen.nl\/de-leefomgeving\/populatie\/verspreiding [Last accessed: November 9 2021]."},{"key":"e_1_3_8_17_1","unstructured":"Knol F. [Status development of neighbourhoods in the Netherlands 1998-2010]. [Article in Dutch]. Den Haag: Sociaal en Cultureel Planbureau 2012."},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S247575"},{"key":"e_1_3_8_19_1","first-page":"923","article-title":"E, et al. Erythema migrans in the immunocompromised host","volume":"111","author":"Maraspin V","year":"1999","unstructured":"Maraspin V, , Lotric-Furlan S, , Cimperman J, Ruzi\u0107-Sablji\u0107 E, et al. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr, 1999; 111:923\u2013932.","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_3_8_20_1","unstructured":"National Institute for Public Health and the Environment (RIVM). CBO guideline Lyme disease July 2013. 2013. Available at https:\/\/www.rivm.nl\/documenten\/cbo-richtlijn-lymeziekte-juli-2013 [Last accessed: March 28 2022]."},{"key":"e_1_3_8_21_1","unstructured":"National Institute for Public Health and the Environment (RIVM). Spread of tick-borne encephalitis virus in the Netherlands. Bilthoven 2020. Available at https:\/\/www.rivm.nl\/en\/news\/spread-of-tick-borne-encephalitis-virus-in-netherlands [Last accessed: August 31 2021]."},{"key":"e_1_3_8_22_1","unstructured":"Nature Today. Tekenbeten: pieken en dalen in 2018. 2019. Available at https:\/\/www.naturetoday.com\/intl\/nl\/nature-reports\/message\/?msg=25116 [Last accessed: May 9 2022]."},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040145"},{"key":"e_1_3_8_24_1","doi-asserted-by":"crossref","unstructured":"Overbeek JA Swart KMA Houben E Beest FJAP-V et al. Completeness and representativeness of the PHARMO general practitioner (GP) data: A comparison with national statistics. 2022. Available at https:\/\/doi.org\/10.2147\/CLEP.S389598","DOI":"10.2147\/CLEP.S389598"},{"key":"e_1_3_8_25_1","unstructured":"Stigas. Week van de teek. Woerden 2021. Available at https:\/\/www.weekvandeteek.nl [Last accessed: August 31 2021]."},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2014.00238"},{"key":"e_1_3_8_27_1","unstructured":"tekenradar.nl. tekenradar.nl. 2012. Available at https:\/\/www.tekenradar.nl [Last accessed: March 29 2022]."},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028064"},{"key":"e_1_3_8_29_1","unstructured":"van den Wijngaard CC Brown V Harms M van Pelt W et al. National Institute of Public Health and the Environment (RIVM) Centre for Infectious Disease Control Bilthoven The Netherlands. Increase in the incidence and burden of Lyme borreliosis in the Netherlands between 2014 and 2017. 2019. Available at https:\/\/www.rivm.nl\/sites\/default\/files\/2019-04\/19.%20Hofhuis_Lyme%20borreliosis.pdf [Last accessed: March 28 2022]."},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13814788.2020.1732347"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01851-06"}],"container-title":["Vector-Borne and Zoonotic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/vbz.2022.0048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vbz.2022.0048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vbz.2022.0048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:02:07Z","timestamp":1777590127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/vbz.2022.0048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1089\/vbz.2022.0048"],"URL":"https:\/\/doi.org\/10.1089\/vbz.2022.0048","relation":{},"ISSN":["1530-3667","1557-7759"],"issn-type":[{"value":"1530-3667","type":"print"},{"value":"1557-7759","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}